TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8705220
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of norfloxacin twice daily for one day (in patients with risk factors)
Study: 1846868
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) alone
Study: 12579102
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg)
Study: 1755948
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg)
Study: 9404431
Drug: Antihypertensive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatments
Study: 24696507
Drug: PF‐04494700 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04494700 60 mg/day × 6 days, then 20 mg daily (high dose)
Study: 24696507
Drug: PF‐04494700 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04494700 15 mg/day × 6 days, then 5 mg daily (low dose)
Study: 15297165
Drug: 4‐HPR (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐HPR (200 mg/day)
Study: 11270943
Drug: Zafirlukast 40
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast 40 mg twice daily
Study: 11270943
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 88 microg or salmeterol 42 microg
Study: 9840560
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of 0.5% bupivacaine before incision (Treatment group A)
Study: 9840560
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo before skin incision and bupivacaine after laparoscopy (Treatment group B)
Study: 9840560
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo before and after laparoscopy (Treatment group C)
Study: 8206772
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three preparatory informational treatments
Study: 2648645
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 micrograms by inhalation)
Study: 10599554
Drug: Tibolone +
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone + fluoride (2.5 mg of tibolone + 26.4 mg of fluoride daily for 2 years)
Study: 10599554
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + fluoride (placebo + 26.4 mg of fluoride daily for 2 years)
Study: 2024543
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 to 40 mg daily, mean 18.3 mg)
Study: 6168856
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg digitoxin
Study: 6168856
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg digitoxin
Study: 6168856
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg digoxin
Study: 24472398
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg OROS hydromorphone
Study: 24472398
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg OROS hydromorphone
Study: 24472398
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg OROS hydromorphone
Study: 24472398
Drug: 64 mg
Normalized name: sulfur 64 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 mg OROS hydromorphone
Study: 24472398
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg naltrexone (concomitant with hydromorphone)
Study: 20639832
Drug: Parenteral amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amino acid (5%) supplementation
Study: 20639832
Drug: Usual nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual nutritional management (10% intravenous dextrose and subsequent enteral feeding)
Study: 17931979
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose then 75 mg daily)
Study: 11909567
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum lipoprotein(a) (≥20 mg/dl) and high low-density lipoprotein (LDL) cholesterol (≥3.63 mmol/L [≥140 mg/dl])
Study: 11909567
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum lipoprotein(a) (≥20 mg/dl) and high low-density lipoprotein (LDL) cholesterol (≥3.63 mmol/L [≥140 mg/dl]) combined with type 2 diabetes mellitus
Study: 9817951
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (part of a multidisciplinary treatment package)
Study: 9817951
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cognitive behavioural therapy)
Study: 2695151
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg/day for three months)
Study: 25200570
Drug: Dapagliflozin 5
Normalized name: dapagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 5 mg twice daily
Study: 24054381
Drug: Polypropylene mesh
Normalized name: polypropylene (30000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypropylene mesh (PM) implant
Study: 12360156
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) therapy
Study: 12360156
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) therapy with GP IIb/IIIa receptor antagonists
Study: 9469979
Drug: Radiosensitizer tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiosensitizer tablets Nimorazol given 1 1/2 hours before radiation, six fractions weekly for patients with squamous cell cancer in the supraglottic region, pharynx and oral cavity.
Study: 9469979
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (specific details not provided).
Study: 2665110
Drug: Arthritis Self‐management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthritis Self‐management Course (ASMC) + bi‐monthly arthritis newsletter
Study: 141020
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy after subarachnoid injection of 0.25% procaine
Study: 141020
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy after 1% procaine sensory and motor blockade
Study: 27264267
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus gemcitabine (DG) - docetaxel 30 mg/m2 plus gemcitabine 900 mg/m2 i.v. on days 1 and 8, every 3 weeks
Study: 27264267
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (G) - gemcitabine 1200 mg/m2 i.v. on days 1 and 8, every 3 weeks
Study: 27264267
Drug: Instrumental Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumental Activities of Daily Living (IADL) score < 7
Study: 27264267
Drug: Instrumental Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumental Activities of Daily Living (IADL) score ≥ 7
Study: 24483110
Drug: Jianbu Tongluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianbu Tongluo Xunzheng Liquid (JTXL), fumigated for 30 min once daily for 10 times (3 courses total)
Study: 24483110
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of JTXL fumigation and Sodium Hyaluronate Injection (SHI), 3 mL each time, once per 6 days for 5 times
Study: 24483110
Drug: Sodium Hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Hyaluronate Injection (SHI), 3 mL each time, once per 6 days for 5 times
Study: 17853748
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (Jiaji EA plus laser needle-knife)
Study: 8267111
Drug: Monosialoganglioside (GM1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosialoganglioside (GM1) 100 mg/day i.m. for 6 weeks
Study: 3115131
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg b.w. flecainide
Study: 27056702
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) after RME (n=10)
Study: 23616511
Drug: Psychosocial stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial stimulation (9 months of weekly play sessions at home)
Study: 23616511
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment (30 mg daily for 6 months)
Study: 21039349
Drug: Perisciatic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perisciatic infusion of ropivacaine 2 mg/ml at a rate of 5 ml/h
Study: 21039349
Drug: Perisciatic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perisciatic infusion of ropivacaine 2 mg/ml at a rate of 8 ml/h
Study: 9048325
Drug: Goniometric measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goniometric measurement by inexperienced testers (physical therapy students)
Study: 9048325
Drug: Visual estimation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual estimation by inexperienced testers (physical therapy students)
Study: 8393273
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose intensity regimens
Study: 3554461
Drug: Clindamycin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin + Gentamycin (C + G)
Study: 3554461
Drug: Metronidazole +
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole + Gentamycin (M + G)
Study: 31755809
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVA) 2.0 mg
Study: 31755809
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR) 0.5 mg
Study: 26204351
Drug: Daily foetal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily foetal movement counting from 28 weeks' gestation (n = 100)
Study: 23937186
Drug: Wise feedback
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wise feedback (treatment condition)
Study: 15615822
Drug: Combined ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined ramipril at 5 mg/d and valsartan at 80 mg/d with increased furosemide dosage
Study: 15615822
Drug: Valsartan at
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan at 160 mg/d
Study: 15615822
Drug: Combined ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined ramipril at 5 mg/d and valsartan at 80 mg/d
Study: 15615822
Drug: Ramipril at
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril at 10 mg/d
Study: 9605723
Drug: Withholding treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding treatment (no AEDs)
Study: 9605723
Drug: Subsequent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent treatment regimens after 3 failures
Study: 9605723
Drug: Overall outcome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall outcome of epilepsy treatment
Study: 2660559
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g sucralfate daily
Study: 30132821
Drug: Neostigmine 2.5
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.5 mg with glycopyrrolate 450 μg (first dose)
Study: 30132821
Drug: Neostigmine 2.5
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.5 mg with glycopyrrolate (second dose)
Study: 30132821
Drug: Neostigmine 2.5
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.5 mg with glycopyrrolate (first dose)
Study: 30132821
Drug: Neostigmine 2.5
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.5 mg with glycopyrrolate (first and second doses)
Study: 28251295
Drug: Daily pin
Normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pin care (group A)
Study: 28251295
Drug: Weekly pin
Normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly pin care (group C)
Study: 21165642
Drug: Nutrient ingestion
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient ingestion (24 g whey, 4.8 g leucine, 50 g maltodextrin)
Study: 11544839
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of progestins and anticoagulants (500 mg, i.v., for 10 days for AH; 20 days for moderately- and poorly-differentiated cell CAC)
Study: 11544839
Drug: Preoperative progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative progestin therapy without anticoagulants
Study: 3006980
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg b.w. propranolol
Study: 29057618
Drug: bococizumab 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: bococizumab 0.25 mg/kg
Study: 29037448
Drug: bococizumab 1
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bococizumab 1 mg/kg
Study: 29037448
Drug: bococizumab 3
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bococizumab 3 mg/kg
Study: 29037448
Drug: bococizumab 6
Normalized name: brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bococizumab 6 mg/kg
Study: 29057618
Drug: bococizumab 6
Normalized name: brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bococizumab 6 mg/kg (all three doses)
Study: 18314215
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg UDCA
Study: 18314215
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg UDCA
Study: 18314215
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg UDCA
Study: 18314215
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of UDCA
Study: 8410645
Drug: Experimental oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental oral intervention (taste, smell, and oral tactile stimulation)
Study: 3102387
Drug: Single 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 800 mg dose of ofloxacin (32 patients)
Study: 3102387
Drug: Single 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 400 mg dose of ofloxacin (55 patients)
Study: 3102387
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a day dose of 600 mg ofloxacin (34 patients)
Study: 3102387
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ofloxacin twice a day for 7-10 days (19 patients with urinary tract infection)
Study: 3102387
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ofloxacin twice a day for 7-10 days (8 patients with enteric fever)
Study: 25874951
Drug: Rebamipide 300
Normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide 300 mg three times daily for 8 weeks
Study: 21407110
Drug: 1 ng/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ng/mL Escherichia coli lipopolysaccharide (LPS)
Study: 21407110
Drug: 5 ng/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ng/mL Escherichia coli lipopolysaccharide (LPS)
Study: 19216298
Drug: Topical skin
Normalized name: Betadine 7.5% Topical Skin Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical skin protectant lotion (IB1)
Study: 15198188
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 7 days (288 patients)
Study: 11844898
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg eletriptan
Study: 11907491
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg almotriptan
Study: 16190915
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg naratriptan
Study: 11728541
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg eletriptan
Study: 11728541
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg and 5 mg zolmitriptan
Study: 19175613
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg eletriptan
Study: 10233200
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg rizatriptan
Study: 9296454
Drug: Antioxidants (n‐acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (n‐acetylcysteine 150 mg/kg for 30 min then 20 mg/kg/h plus bolus doses of 1 g ascorbic acid and 400 mg alpha‐tocopherol)
Study: 8420296
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Pravastatin + Gemfibrozil)
Study: 3749299
Drug: Caffeine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (20 to 160 mg)
Study: 3749299
Drug: Caffeine (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (160 mg)
Study: 3749299
Drug: Caffeine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (various doses including 0, 20, 40, 80, 160 mg)
Study: 19486913
Drug: Caffeine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (80 mg)
Study: 31426272
Drug: SEDDS-CBD (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEDDS-CBD (25 mg)
Study: 25439055
Drug: Pre-emptive early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive early interventions (PEI) including skill training for parents of younger children and courses in emotional well-being skills based on cognitive behavioural therapy for older children and youth.
Study: 23311248
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol and midazolam
Study: 19220845
Drug: Straumann implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Straumann implants
Study: 15248876
Drug: Brånemark implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark implants
Study: 18569900
Drug: Brief office
Normalized name: Office First Aid Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief office intervention (BOI) consisting of four weekly individual sessions lasting 10 to 40 minutes each, incorporating motivational interviewing and cognitive-behavioral techniques.
Study: 12480588
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) in combination with radiotherapy
Study: 28696503
Drug: Standard-dose P.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose P. pratense allergoid (6000 TU)
Study: 28696503
Drug: High-dose P.
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose P. pratense allergoid (18000 TU)
Study: 25681064
Drug: SSM‐VIMT (malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSM‐VIMT (malaria transmission blocking vaccine)
Study: 1932407
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluoxetine
Study: 16423942
Drug: 1.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL/kg of iohexol over 35 sec (Group A)
Study: 16423942
Drug: 1.7 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 mL/kg of iohexol over 35 sec (Group B)
Study: 16423942
Drug: 2.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL/kg of iohexol over 35 sec (Group C)
Study: 16423942
Drug: 1.7 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 mL/kg of iohexol over 25 sec (Group D)
Study: 9737753
Drug: Fluid formulation
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid formulation with 157 Na (270 mOsm x kg(-1))
Study: 9737753
Drug: Fluid formulation
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid formulation with Performance (19.6 mEq x L(-1) Na, 380 mOsm)
Study: 9737753
Drug: Fluid formulations
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid formulations with 19.6 Na or 19.6 Na + glucose
Study: 8070505
Drug: Diltiazem 90
Normalized name: diltiazem 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 90 mg controlled-release (CR) tablet bd
Study: 8070505
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg controlled-release (CR) tablet bd
Study: 8070505
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg immediate-release (IR) tablet tid
Study: 2660558
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg three times a day and 400 mg at night
Study: 2660558
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g four times a day orally for four weeks
Study: 25119686
Drug: Pre-bronchodilator microspirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-bronchodilator microspirometry test (FEV1/FEV6 <0.73)
Study: 22361399
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg intravenously)